Perrigo’s Irish Move Sets Stage For International Boost, Net Revenue Gain
This article was originally published in The Tan Sheet
Executive Summary
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.
You may also be interested in...
Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
Mylan Continues Busy Year With Perrigo Offer
Still integrating businesses gained from Abbott and Famy Care, Mylan proposes a $205-per-share bid for Perrigo, which itself just closed a $4.5 billion takeout of Omega Pharma.